Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises on listing of Deutsche Bank’s exchange traded funds on NASDAQ OMX Stockholm
Mandate

Vinge advises on listing of Deutsche Bank’s exchange traded funds on NASDAQ OMX Stockholm

April 20, 2010

Vinge has advised Deutsche Bank in connection with the listing of db x-trackers, Deutsche Bank’s trading platform for exchange traded funds (“ETFs”) on NASDAQ OMX Stockholm. Up to now, 21 ETFs have been listed and are currently being traded on NASDAQ OMX Stockholm.

Vinge also advised during the negotiations with Euroclear Sweden AB regarding clearing and settlement for db x-trackers EFTs prior to trading on NASDAQ OMX Stockholm.

Vinge’s team consisted of Fredrik Wilkens (responsible partner), Ola Sandersson (partner), Dan Hanqvist (clearing and settlement), Maria Schultzberg (tax issues), Emma Stuart-Beck (project manager), Katarina Rykowska, Katarina Rodell and Ulrica Åkesson.

 

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026